Dr. Reddy's Laboratories heads into its May 18 earnings call with short sellers at their most active in weeks — and fresh evidence of a significant Q4 stumble already in the market.
The short-selling setup is the most striking feature of the current positioning. Estimated short interest climbed 16% in a single week to roughly 15.8 million shares, with the bulk of that move arriving after May 8. The ORTEX short score holds in the mid-50s, consistent with elevated but not extreme bearish conviction. Borrow costs remain low at 0.56% annualised, down slightly on the week, and the lending market is not particularly tight — availability is still well inside normal ranges, pointing to no meaningful squeeze pressure for existing short holders.
The options market tells a more nuanced story. The put/call ratio has eased to 0.65 after spiking above 1.2 in the days following the initial results announcement — the PCR reached 1.23 on May 12, when the stock fell 1.1% on the day. That earlier defensive surge has now partially unwound, with the current reading sitting roughly 0.7 standard deviations above its 20-day mean of 0.35. Taken together, the options and short interest data describe a market that was caught off-guard by the print, moved quickly to hedge, and is now recalibrating — rather than one in full defensive retreat.
The fundamental backdrop is sobering. Q4 revenues fell 11.6% to Rs 7,516 crore, and net profit collapsed 86.2% — a miss that analysts flagged as 16% below EPS expectations and that sent the NYSE-listed ADR to a new 52-week low. The stock has since bounced 3.8% in a single session to $13.49, clawing back some ground but still essentially flat on the month. The May 18 call will give management its first extended opportunity to explain the margin deterioration and frame the recovery path. On the institutional side, BlackRock added 374,617 shares as of April 30, and Boston Partners built a position by more than 4 million shares in Q1 — a sign that some long-only money stepped in ahead of the results, though the size of the earnings miss will test that conviction. There is also a tentative FDA approval for Empagliflozin announced this week, a small positive for the US generics pipeline that may come up on the call.
The analyst record in the snapshot is too dated to carry weight — coverage data predates the current price level by years. What remains clear is that the Monday call is primarily about the severity of the Q4 damage, whether management can credibly restore margin guidance, and how much of the decline was one-time versus structural.
See the live data behind this article on ORTEX.
Open RDY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
